SEC Filing Document

Company: DUKE Robotics Corp.
Ticker: DUKR
CIK: 1638911
Filing Type: DRS
Document Type: DRS
Date Filed: 2025-12-22
Accession Number: 0001213900-25-124553
Exchange: OTC
SIC Code: 3721
SIC Description: Aircraft
URL: https://www.sec.gov/Archives/edgar/data/1638911/000121390025124553/filename1.htm

Chunk 4 of 51
Word Count: 1498
Character Count: 9172

Document Content:

Our management team may not be able to successfully implement our business strategies; ● Significant disruptions of our information technology systems or breaches of our data security could adversely affect our business; ● A decline in the price of our common stock could affect our ability to raise working capital and adversely impact our ability to continue operations; ● The requirements of being a public company may strain our resources and distract management; ● Future changes in financial accounting standards or practices may cause adverse unexpected financial reporting fluctuations and affect reported results of operations. Please see “Risk Factors” beginning on page 9 for a more detailed discussion of these risks. Additional risks, beyond those summarized above or discussed under the caption “Risk Factors” or described elsewhere in this prospectus may also materially and adversely impact our business, operations or financial results. Summary of the Offering Issuer: DUKE Robotics Corp.

Securities offered by us:	[   ] Units, based on a $[__] public offering price per Unit, each Unit consisting of one share of our common stock and one warrant to purchase one share of our common stock. Each warrant will have an exercise price of $[   ] per share ([ ]% of the public offering price of each Unit), is exercisable immediately and will expire [five (5)] years from the date of issuance. The Units will not be certificated or issued in stand-alone form. The shares of our common stock and the warrants comprising the Units must be purchased together in this offering as Units and are immediately separable upon issuance and will be issued separately in this offering.

Number of shares of common stock offered by us:	[   ] shares.

Number of warrants offered by us:	Warrants to purchase up to [   ] shares of common stock.

Public offering price:	$[   ] per Unit. The actual number of Units we will offer will be determined based on the actual public offering price and the reverse split ratio will be determined based on the stock price.

Shares of common stock outstanding prior to the offering (1) :	[   ]

Shares of common stock outstanding after the offering (2) :	[   ] shares (assuming no exercise of the over-allotment option and that
none of the warrants issued in this offering and none of the Representative’s Warrants are exercised).

Over-allotment option:	We have granted a 45-day option to the representative of the underwriters to purchase up to [   ] additional shares of common stock at a price of $[   ] per share (based on an offering price of $[   ] per Unit) and/or [   ] additional warrants at a price of $0.0001 per warrant less, in each case, the underwriting discounts payable by us, solely to cover over-allotments, if any. If the representative of the underwriters exercises the option in full, the total underwriting discounts and commissions payable by us will be $[   ] and the total proceeds to us, before expenses, will be $[   ].

Use of proceeds:	We estimate that we will receive net proceeds of approximately $[   ] from our sale of Units in this offering, after deducting underwriting discounts and estimated offering expenses payable by us (assuming no exercise of the underwriter’s over-allotment options, the warrants included in the Units or the Representative’s Warrants (as defined below) offered hereby). We intend to use the net proceeds of this offering to provide funding for research and development, sales force expansion, marketing, business
development and potential acquisitions and for general working capital. See “Use of Proceeds.”

Description of the warrants:	The exercise price of the warrants is $[   ] per share ([_]% of the public offering price of one Unit). Each warrant is exercisable for one share of common stock, subject to adjustment in the event of stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock as described herein. A holder may not exercise any portion of a warrant to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% of the outstanding common stock after exercise, as such percentage ownership is determined in accordance with the terms of the warrants, except that upon notice from the holder to us, the holder may waive such limitation up to a percentage, not in excess of 9.99%. Each warrant will be exercisable immediately upon issuance and will expire five years after the initial issuance date. The terms of the warrants will be governed by a Warrant Agreement, dated as of the effective date of this offering, between us and Direct Transfer, LLC, a subsidiary of Issuer Direct Corporation, as the warrant agent (the “Warrant Agent”). This prospectus also relates to the offering of the shares of common stock issuable upon exercise of the warrants. For more information regarding the warrants, you should carefully read the section titled “Description of Securities—Warrants” in this prospectus.

Representative’s Warrants:	The registration statement of which this prospectus is a part also registers for sale warrants (the “Representative’s Warrants”) to purchase up to [   ] shares of our common stock (based on an offering price of $[   ] per Unit) to Maxim Group LLC (the “Representative”) at an exercise price of $[_] ([_]% of the public offering price of the Units), as the representative of the several underwriters, as a portion of the underwriting compensation payable to the Representative in connection with this offering. The Representative’s Warrants will be exercisable at any time, and from time to time, in whole or in part, commencing six months following the effective date of the registration statement of which this prospectus is a part and will expire five years from such effective date. Please see “Underwriting—Representative’s Warrants” for a description of these warrants.

Trading symbol:	Our common stock is currently quoted on the OTCQB under the symbol
“DUKR.” We intend to apply to have our common stock and warrants listed on Nasdaq under the symbol “DUKR” and
“DUKRW,” respectively , and if necessary, we intend to effect a reverse stock split of our common stock in order to obtain
Nasdaq approval for our listing of our common stock. We cannot guarantee that such reverse stock split will occur based on any specific
ratio, that such reverse stock split will be necessary or will occur in connection with the uplist of our common stock to Nasdaq, or that
Nasdaq will approve our initial listing application for our common stock upon such reverse stock split. If our listing application is
not approved by Nasdaq, we will not be able to consummate this offering and will terminate the offering.

Reverse stock split:	We expect to effect a [   ]-for-[   ] reverse stock split of our outstanding common stock following the effective time of the registration statement of which this prospectus forms a part but prior to the closing of this offering. We intend to effectuate the reverse split of our common stock in a ratio to be determined by the Board.

Risk factors:	Investing in our securities involves a high degree of risk and purchasers of our securities may lose their entire investment. See “Risk Factors” and the other information included and incorporated by reference into this prospectus for a discussion of risk factors you should carefully consider before deciding to invest in our securities.

Lock-up Agreements:	We and our directors, officers and certain principal shareholders have agreed with the Representative not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock for a period of 180 days after the date of this prospectus. See “Underwriting—Lock-Up Agreements.”

Transfer Agent and Registrar:	The transfer agent and registrar for our common stock is Direct Transfer, LLC, a subsidiary of Issuer Direct Corporation, with its business address at One Glenwood Ave, Suite 1001 Raleigh, NC 27603.

(1)	Unless we indicate otherwise,
the number of shares of our common stock outstanding is based on 54,218,813 shares of common stock outstanding [_], 2025, do not give
effect to our planned reverse stock split at a ratio of [   ], and do not include, as of that date:

(2)	The number of shares of our common
stock outstanding after the offering gives effect to our planned reverse stock split at a ratio of [   ], but does not
include:

●	15,500,000  shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $0.65 per share;

●	[   ] shares of our common stock issuable upon exercise of warrants to be issued in this offering;

●	[   ] shares of our common stock issuable upon exercise of the Representative’s Warrants;

●	4,496,812 shares of our common stock issuable upon exercise of outstanding options at a weighted average exercise price of $0.54 per share; and

●	4,503,188 shares of our common stock that are reserved for equity awards that may be granted under our existing equity incentive plans.